FindTrial
Sign In

comparison of bilastine with cetirizine or fexofenadine in chronic spontaneous urticaria

Sequential comparison of bliastine with cetirizine or fexofenadine in chronic spontaneous urticaria

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025959
Enrollment
44
Registered
2020-06-18
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L501- Idiopathic urticaria

Interventions

Intervention1: Bilastine: 44 patients will be started on bilastine 20 mg OD for a period of 3 weeks to study the efficacy of the drug,followed by division into 2 groups of 22 each.22 patients will be

Sponsors

Department of Dermatology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with chronic spontaneous urticaria , wheals and pruritis persiting for most of the days , for more than 6 weeks 2. patients more than 12 years of age.

Exclusion criteria

Exclusion criteria: 1.Patients taking systemic steroid or immunosuppressive therapy in the last 2 weeks 2. Patients with severe life threatening illness 3. Pregnant and lactating mothers.

Design outcomes

Primary

MeasureTime frame
To study the clinical efficacy of bliastine in Indian population and compare its efficacy with cetirizine or fexofenadine in chronic spontaneous urticaria.Timepoint: 0,1,2,3,4,5,6 weeks—

Secondary

MeasureTime frame
To compare adverse effects of bilastine with cetirizine or fexofenadine in chronic spontaneous urticaria.Timepoint: 0,1,2,3,4,5,6 weeks—

Countries

India

Contacts

Public ContactProfessor Mala Bhalla

Government Medical College and Hospital, Chandigarh

malabhalla@yahoo.co.in9646121545

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026